PATIENT SUPPORT PROGRAMS

START WITH TREMFYA^®
SO SIMPLE TRIAL PROGRAM

The TREMFYA^® So Simple Trial Program provides patients their first dose of TREMFYA^® so they may determine with their provider if it is right for them.

FORM for easy enrollment

COST to patient

Shipment can be authorized within 3 BUSINESS DAYS after prescription.^*

This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends.

^*Shipment can be authorized within 3 business days of submitting a prescription pending patient program opt-in and scheduling shipment.

FILL OUT AN ENROLLMENT FORM

FOR COMMERCIALLY INSURED PATIENTS STAY ON TREMFYA^®

JANSSEN CAREPATH SAVINGS PROGRAM

Eligible patients pay

per injection

with a $20,000 maximum program beneﬁt per calendar year

See full program requirements at Tremfya.JanssenCarePathSavings.com.

Patients will receive TREMFYA^® at no-cost until they receive insurance coverage approval

See full program requirements at JanssenCarePath.com/Tremfya/Janssen-Link.

Both programs are unavailable to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration.

ACCESS EXPRESS ENROLLMENT

These programs are for medication only. Terms expire at the end of each program year and may change.

JANSSEN CAREPATH IS YOUR ONE SOURCE FOR ACCESS, AFFORDABILITY, AND TREATMENT SUPPORT FOR YOUR PATIENTS

Access support

to help navigate payer processes

Janssen CarePath helps verify insurance coverage for your patients taking TREMFYA® and provides reimbursement information.

Online Benefits Investigation and Prior Authorization Support

Affordability support

to help your patients start and stay on the treatment you prescribe

Janssen CarePath can help you find out what affordability assistance may be available for your patients taking TREMFYA®.

Comprehensive Provider Portal to enroll eligible patients in the Janssen CarePath Savings Program and more

Express Enrollment Site for Savings Program for TREMFYA®

Treatment support

to help your patients get informed and stay on TREMFYA®

Janssen CarePath provides additional support to your patients, including patient education, web-based resources, and personalized reminders.

Learn More

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday to Friday,
8:00 AM to 8:00 PM ET. Multilingual phone support available.***

VISIT JanssenCarePath.com

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

PATIENT SUPPORT PROGRAMS

START WITH TREMFYA^®
SO SIMPLE TRIAL PROGRAM